Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious ...

Richard Saperstein, Chief Investment Officer at Treasury Partner, joins CNBC's Halftime Report to detail his latest portfolio ...

Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true. However, dividends are paid out of cash flow, not earnings, so a payout ratio ...

In the lucrative obesity drug race, there is Eli Lilly — and then there's everybody else. A pair of headlines Monday reinforced Lilly's dominance: Its lone commercial rival, Novo Nordisk , released ...

The FDA’s reversal of its earlier refusal to review mRNA-1010, the seasonal flu vaccine being developed by Moderna, accelerated a revival of Moderna shares that has been in progress over recent months ...

Pfizer's dividend yield is a lofty 6.2%. That's well above the 1.1% yield offered by the S&P 500 index and the 1.7% yield of the average pharmaceutical stock. And the company recently provided ...

BioNTech has sued Moderna, alleging its mNEXSPIKE vaccine uses patented COVID vaccine technology without authorization.

Is Pfizer’s 6% dividend yield a rare value opportunity in 2026, or is Wall Street pricing in bigger risks ahead?

​Pfizer Inc. (NYSE: PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced positive results from its key BREAKWATER trial, which is testing ...

Johnson & Johnson is upgraded to Buy and Pfizer to Hold reflecting improved profitability outlooks post-Q4 2025 earnings.

Learn more about whether IDEAYA Biosciences, Inc. or Legend Biotech Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.